Prime Medicine, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Prime Medicine is a clinical-stage biotechnology company developing genetic therapies using its Prime Editing platform. Results are unaudited.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Collaboration revenue | $0.6 million | No revenue reported |
| Research and development expense | $37.8 million | $30.9 million |
| General and administrative expense | $11.2 million | $9.2 million |
| Total operating expenses | $48.9 million | $40.0 million |
| Operating loss | $48.3 million | $40.0 million |
| Net loss | $45.8 million | $39.4 million |
| Basic and diluted loss per share | $0.44 | $0.44 |
| Net cash used in operating activities | $67.7 million | $41.6 million |
Revenue was collaboration revenue; the company had no product sales and does not expect product revenue for several years, if ever. Gross margin is not applicable as presented: the filing reports no cost-of-revenue line. R&D expense rose $6.9 million, mainly from personnel and facility costs; G&A rose $2.0 million, primarily from personnel costs. Other income was $2.7 million, including a $1.2 million gain in the fair value of the Beam-related investment, compared with $0.4 million of other income in Q1 2023.
At March 31, cash, cash equivalents and investments were $210.7 million, excluding $13.5 million of restricted cash. Current assets were $217.7 million and current liabilities $24.4 million. Total assets were $311.4 million; total liabilities were $67.6 million, including $43.8 million of operating lease liabilities and a $6.0 million research and development funding liability. The filing reports no conventional borrowings. Accumulated deficit was $537.1 million.
Cash, cash equivalents and restricted cash increased $52.6 million during the quarter. Operating activities used $67.7 million and investing activities used $37.0 million; financing activities provided $157.3 million. The investing outflow primarily reflected net purchases of marketable securities and property and equipment purchases.
Material changes and notable items
- In February 2024, the company sold 22.56 million common shares at $6.25 per share and pre-funded warrants for 3.20 million shares. It reported approximately $150.9 million in net offering proceeds after costs. The financing materially increased cash and stockholders’ equity and diluted existing shareholders.
- Operating expenses and operating cash use increased year over year; net loss widened, while reported loss per share remained $0.44, reflecting a larger weighted-average share count.
- A new lease component commenced in March 2024, adding a $44.9 million right-of-use asset and $33.6 million lease liability. The company expects up to approximately $208.7 million of payments over the initial ten-year lease term, subject to lease credits; two other components were expected to commence in 2025.
- The company paid a $13.5 million settlement to Myeloid Therapeutics in Q1, resolving disputes under a settlement accrued at year-end 2023.
- The company received $6.0 million under its agreement with the Cystic Fibrosis Foundation, recorded as a research and development funding liability.
Outlook, risks and contingencies
Management expects operating losses and negative operating cash flows for the foreseeable future, with R&D and other expenses expected to increase as programs advance. The filing states that available cash, cash equivalents and investments are expected to fund operations into the third quarter of 2025; the financial statement note separately says resources should be sufficient for at least the next twelve months from issuance. These are estimates based on assumptions and could prove inaccurate. Management expects to need additional capital and warns that financing may be unavailable or unfavorable, potentially requiring delays, reductions, or licensing of development programs.
After quarter-end, in April 2024, the FDA cleared the IND for PM359 for chronic granulomatous disease, allowing the company to initiate a multinational Phase 1/2 trial. The filing describes the trial as designed to assess safety, biological activity and preliminary efficacy; outcomes and timing remain uncertain.
Key risks include the early-stage nature of the pipeline, clinical and regulatory uncertainty, manufacturing and third-party dependence, intellectual-property protection, competition, employee retention, and the need for additional financing. The company reported no material changes to previously disclosed risk factors and no legal proceedings considered probable to have a material adverse effect. It also reported no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the stated cash runway into Q3 2025 remains achievable as clinical and platform spending increases.
- How the PM359 Phase 1/2 trial proceeds, including enrollment, safety, biological activity and timing.
- The implications of the February offering and pre-funded warrants for fully diluted share count; 120,030,813 common shares were outstanding on May 1, 2024.
- Future cash obligations under the Cambridge lease, including commencement of the remaining lease components.
- The terms, milestones and potential repayment or other obligations associated with the $6.0 million Cystic Fibrosis Foundation funding.
- Whether collaboration revenue develops into a material source of funding, given the absence of product revenue and the company’s stated need for additional capital.